Skip to content
Review Open access

Algorithmic Determinants of Performance Heterogeneity in Whole-Genome Sequencing-Based Prediction of Drug Resistance in Mycobacterium tuberculosis: A Systematic Review and Meta-Analysis

Aug 2026 · Microorganisms · Vol 14, pp. 1824 · 0 citations · 42 references
Medicine

TL;DR

WGS-based bioinformatic tools provide highly specific and generally sensitive predictions of Mycobacterium tuberculosis resistance for first-line drugs across diverse clinical settings and should use prospective head-to-head evaluations on shared, geographically diverse isolate collections, alongside continued improvement of resistance catalogues and external validation.

Abstract

Whole-genome sequencing (WGS) is an increasingly adopted platform for predicting drug resistance in Mycobacterium tuberculosis; however, diagnostic accuracy varies substantially across bioinformatic tools and analytical frameworks, generating considerable uncertainty for clinical laboratory implementation. We conducted a prospectively registered (PROSPERO: CRD420261342739), PRISMA-DTA-compliant systematic review and meta-analysis of diagnostic accuracy studies. PubMed (MEDLINE), Embase, Web of Science, and Cochrane CENTRAL were searched from 1 January 2000 through 28 January 2026. Primary overall sensitivity and specificity were estimated using a tool-level bivariate random-effects model. Exploratory subgroup analyses and meta-regression examined the association between algorithm category and diagnostic-performance heterogeneity. Twenty-eight drug-level evaluations from seven tools (rifampicin, isoniazid, ethambutol, and pyrazinamide for each tool) were compiled from the extracted 2 × 2 data. For the primary tool-level composite analysis, pooled sensitivity was 0.930 (95% CI: 0.907–0.948) and pooled specificity was 0.962 (95% CI: 0.929–0.981). In secondary drug-specific analyses, sensitivity was highest for rifampicin (0.960, 95% CI: 0.934–0.976) and isoniazid (0.933, 95% CI: 0.906–0.953), and lowest for pyrazinamide (0.860, 95% CI: 0.800–0.904). Exploratory tool-level comparisons produced pooled sensitivity estimates of 0.920 for rule-based tools, 0.899 for machine learning tools, and 0.951 for hybrid tools. These comparisons involved only seven tool-level analytic units and cannot disentangle algorithm type from individual tool identity, training data, mutation catalogue version, or validation population. WGS-based bioinformatic tools provide highly specific and generally sensitive predictions of Mycobacterium tuberculosis resistance for first-line drugs across diverse clinical settings. Exploratory differences between tool categories should not be interpreted as causal effects of algorithmic architecture. Future studies should use prospective head-to-head evaluations on shared, geographically diverse isolate collections, alongside continued improvement of resistance catalogues and external validation.

Read PDF

Similar papers

Review Open access Sep 2026

Genotypic Diversity and Recent Transmission Patterns of Mycobacterium Tuberculosis in Ethiopia: a Systematic Review and Meta-analysis

Mycobacterium tuberculosis complex (MTBC) remains a leading cause of global morbidity and mortality. Despite its relatively low mutation and recombination rates, considerable genotypic variation exists, influencing disease progression, transmission, and the emergence of drug resistance. This systematic review...

Haftom Legese, A. G. Wasihun, Hadush Negash et al. · 0 citations
Review Open access Sep 2026

Diagnostic accuracy of rapid integrated molecular testing for major respiratory viral infections: a systematic review and meta-analysis

Background Rapid integrated molecular tests are automated sample-to-answer nucleic acid amplification systems that provide respiratory virus results within approximately 120 min. Because their use ranges from genuine near-patient sites to rapid laboratory workflows, testing environments must be clearly classified. Meth...

Chen-Zi Liu, Dao-Jun Yu · 0 citations
Open access Sep 2026

Updated TB-Profiler: enhanced genotypic antimicrobial resistance prediction and relatedness analysis powered by a database of over 171,000 Mycobacterium tuberculosis genomes

TB-Profiler is a user-friendly bioinformatics tool developed to genotypically profile Mycobacterium tuberculosis from next-generation sequencing data. It provides predictions of drug resistance and assigns sub-lineages to support clinical management of tuberculosis (TB) and public health surveillance. The pla...

J. Phelan, Waritta Sawaengdee, Joseph Thorpe et al. · 0 citations
Open access Aug 2026

Analytical concordance of targeted next-generation sequencing and whole-genome sequencing for Mycobacterium tuberculosis drug resistance and lineage determination in West Java, Indonesia

As drug-resistant tuberculosis (DR-TB) cases rise, resistance detection in a timely manner is essential to lead effective treatment and limit transmission. Targeted next-generation sequencing (tNGS) offers quick results with multiple important drugs covered, but assessments regarding its performance for DR-TB diagnosti...

Gusti Ayu Prani Pradani, A. Alifia, A. P. Syahbaniati et al. · 0 citations
Open access Aug 2026

Clinical utility of targeted next-generation sequencing for rapid detection, species differentiation, drug resistance profiling, and prognostic evaluation in Mycobacterium tuberculosis: a multi-center retrospective cohort study

Background Tuberculosis (TB) remains a global health threat, which is complicated by challenges in distinguishing TB from nontuberculous mycobacteria (NTM) infections and drug resistance. Conventional diagnostics (including culture, Xpert MTB/RIF, AFB smear, T-SPOT.TB, etc.) are limited by inadequate differentiation of...

Ling-Xia Shi, Mingde Ni, Fan Yang et al. · 0 citations
Review Open access Sep 2026

Refining the TCGA Framework: The Pivotal Role of Targeted Next-Generation Sequencing in Resolving Diagnostic Ambiguities in Endometrial Cancer—Systematic Review

The classification of endometrial cancer based on histological examination often fails to accurately predict treatment outcomes for patients. The Cancer Genome Atlas (TCGA) has proposed a new molecular model that more accurately identifies the tumour subtype, enabling more precise treatment. However, its implementation...

Natalia Gierulska, Julia Orzelska, Katarzyna Lachowska et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.